Mesalamine Discontinuation Guidelines

Introduction to Mesalamine Management

• The American Gastroenterological Association (AGA) guidelines for ulcerative colitis management do not recommend tapering mesalamine when discontinuing therapy, as it does not cause physiologic dependence or adrenal suppression 1, 2, 3, 4.

Discontinuation Considerations

• Stopping mesalamine in patients with ulcerative colitis may lead to disease relapse, as it removes the therapeutic effect of the medication 6.
• The AGA and European Crohn's and Colitis Organisation (ECCO) recommend continuing mesalamine indefinitely for maintenance of remission in most patients with ulcerative colitis, particularly those with left-sided or extensive disease 6.

Contrast with Corticosteroids

• The AGA explicitly recommends tapering corticosteroids (such as prednisone or budesonide) when used for ulcerative colitis to avoid adrenal insufficiency 1, 3, 4.

Practical Discontinuation Approach

• When switching from mesalamine to alternative maintenance therapy (such as immunomodulators or biologics), it is possible to stop mesalamine and start the new therapy without overlap or taper 1, 6.